ID   KPBB_HUMAN              Reviewed;        1093 AA.
AC   Q93100; Q8N4T5;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 165.
DE   RecName: Full=Phosphorylase b kinase regulatory subunit beta;
DE            Short=Phosphorylase kinase subunit beta;
GN   Name=PHKB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND ALTERNATIVE SPLICING.
RX   PubMed=8681948; DOI=10.1111/j.1432-1033.1996.0374z.x;
RA   Wuellrich-Schmoll A., Kilimann M.W.;
RT   "Structure of the human gene encoding the phosphorylase kinase beta
RT   subunit (PHKB).";
RL   Eur. J. Biochem. 238:374-380(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [4]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2 (ISOFORMS 2 AND 4),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4 (ISOFORMS 2 AND 4),
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 2),
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 4),
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   VARIANT CYS-770.
RX   PubMed=9326319; DOI=10.1086/515502;
RA   van den Berg I.E.T., van Beurden E.A.C.M., de Klerk J.B.C.,
RA   van Diggelen O.P., Malingre H.E.M., Boer M.M., Berger R.;
RT   "Autosomal recessive phosphorylase kinase deficiency in liver, caused
RT   by mutations in the gene encoding the beta subunit (PHKB).";
RL   Am. J. Hum. Genet. 61:539-546(1997).
RN   [12]
RP   VARIANT GSD9B PRO-118.
RX   PubMed=9402963; DOI=10.1007/s004390050608;
RA   Burwinkel B., Moses S.W., Kilimann M.W.;
RT   "Phosphorylase-kinase-deficient liver glycogenosis with an unusual
RT   biochemical phenotype in blood cells associated with a missense
RT   mutation in the beta subunit gene (PHKB).";
RL   Hum. Genet. 101:170-174(1997).
RN   [13]
RP   VARIANTS LYS-657 AND CYS-770.
RX   PubMed=12825073; DOI=10.1038/sj.ejhg.5200996;
RA   Burwinkel B., Hu B., Schroers A., Clemens P.R., Moses S.W., Shin Y.S.,
RA   Pongratz D., Vorgerd M., Kilimann M.W.;
RT   "Muscle glycogenosis with low phosphorylase kinase activity: mutations
RT   in PHKA1, PHKG1 or six other candidate genes explain only a minority
RT   of cases.";
RL   Eur. J. Hum. Genet. 11:516-526(2003).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-867 AND ARG-877.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Phosphorylase b kinase catalyzes the phosphorylation of
CC       serine in certain substrates, including troponin I. The beta chain
CC       acts as a regulatory unit and modulates the activity of the
CC       holoenzyme in response to phosphorylation.
CC   -!- ENZYME REGULATION: By phosphorylation of various serine residues.
CC       {ECO:0000250}.
CC   -!- PATHWAY: Glycan biosynthesis; glycogen metabolism.
CC   -!- SUBUNIT: Hexadecamer of 4 heterotetramers, each composed of alpha,
CC       beta, gamma, and delta subunits. Alpha (PHKA1 or PHKA2) and beta
CC       (PHKB) are regulatory subunits, gamma (PHKG1 or PHKG2) is the
CC       catalytic subunit, and delta is calmodulin.
CC   -!- INTERACTION:
CC       Q13554:CAMK2B; NbExp=3; IntAct=EBI-740559, EBI-1058722;
CC       Q96RG2:PASK; NbExp=2; IntAct=EBI-740559, EBI-1042651;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Lipid-anchor
CC       {ECO:0000305}; Cytoplasmic side {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q93100-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q93100-2; Sequence=VSP_012445;
CC         Note=Initiator Met-1 is removed. Contains a N-acetylalanine at
CC         position 2. Contains a phosphoserine at position 4.
CC         {ECO:0000244|PubMed:20068231};
CC       Name=3;
CC         IsoId=Q93100-3; Sequence=VSP_012446;
CC       Name=4;
CC         IsoId=Q93100-4; Sequence=VSP_012445, VSP_012446;
CC         Note=Initiator Met-1 is removed. Contains a N-acetylalanine at
CC         position 2. Contains a phosphoserine at position 4.
CC         {ECO:0000244|PubMed:20068231};
CC   -!- PTM: Ser-701 is probably phosphorylated by PKA.
CC   -!- PTM: Although the final Cys may be farnesylated, the terminal
CC       tripeptide is probably not removed, and the C-terminus is not
CC       methylated. {ECO:0000250|UniProtKB:P12798}.
CC   -!- DISEASE: Glycogen storage disease 9B (GSD9B) [MIM:261750]: A
CC       metabolic disorder characterized by hepatomegaly, only slightly
CC       elevated transaminases and plasma lipids, clinical improvement
CC       with increasing age, and remarkably no clinical muscle
CC       involvement. Biochemical observations suggest that this mild
CC       phenotype is caused by an incomplete holoenzyme that lacks the
CC       beta subunit, but that may possess residual activity.
CC       {ECO:0000269|PubMed:9402963}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the phosphorylase b kinase regulatory chain
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X84909; CAA59333.1; -; Genomic_DNA.
DR   EMBL; X84911; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84912; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84913; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84914; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84915; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84916; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84917; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84918; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84919; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84920; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84921; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84922; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84923; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84924; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84925; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84926; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84927; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84928; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84929; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84930; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84931; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84933; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84934; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84935; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84936; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84937; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84938; CAA59333.1; JOINED; Genomic_DNA.
DR   EMBL; X84908; CAA59332.1; -; mRNA.
DR   EMBL; BC033657; AAH33657.1; -; mRNA.
DR   CCDS; CCDS10729.1; -. [Q93100-1]
DR   CCDS; CCDS42161.1; -. [Q93100-4]
DR   PIR; S74250; S74250.
DR   PIR; S74251; S74251.
DR   RefSeq; NP_000284.1; NM_000293.2. [Q93100-1]
DR   RefSeq; NP_001027005.1; NM_001031835.2. [Q93100-4]
DR   RefSeq; XP_005256040.1; XM_005255983.4. [Q93100-3]
DR   RefSeq; XP_005256041.1; XM_005255984.4. [Q93100-4]
DR   UniGene; Hs.78060; -.
DR   ProteinModelPortal; Q93100; -.
DR   BioGrid; 111275; 23.
DR   IntAct; Q93100; 9.
DR   MINT; MINT-1444943; -.
DR   STRING; 9606.ENSP00000313504; -.
DR   ChEMBL; CHEMBL2111324; -.
DR   iPTMnet; Q93100; -.
DR   PhosphoSitePlus; Q93100; -.
DR   BioMuta; PHKB; -.
DR   DMDM; 2499582; -.
DR   EPD; Q93100; -.
DR   MaxQB; Q93100; -.
DR   PaxDb; Q93100; -.
DR   PeptideAtlas; Q93100; -.
DR   PRIDE; Q93100; -.
DR   DNASU; 5257; -.
DR   Ensembl; ENST00000299167; ENSP00000299167; ENSG00000102893. [Q93100-3]
DR   Ensembl; ENST00000323584; ENSP00000313504; ENSG00000102893. [Q93100-1]
DR   Ensembl; ENST00000566044; ENSP00000456729; ENSG00000102893. [Q93100-4]
DR   GeneID; 5257; -.
DR   KEGG; hsa:5257; -.
DR   UCSC; uc002eeu.5; human. [Q93100-1]
DR   CTD; 5257; -.
DR   DisGeNET; 5257; -.
DR   GeneCards; PHKB; -.
DR   GeneReviews; PHKB; -.
DR   HGNC; HGNC:8927; PHKB.
DR   HPA; HPA073380; -.
DR   MalaCards; PHKB; -.
DR   MIM; 172490; gene.
DR   MIM; 261750; phenotype.
DR   neXtProt; NX_Q93100; -.
DR   OpenTargets; ENSG00000102893; -.
DR   Orphanet; 79240; Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency.
DR   PharmGKB; PA33268; -.
DR   eggNOG; KOG3635; Eukaryota.
DR   eggNOG; ENOG410XPJZ; LUCA.
DR   GeneTree; ENSGT00520000055553; -.
DR   HOGENOM; HOG000231477; -.
DR   HOVERGEN; HBG097309; -.
DR   InParanoid; Q93100; -.
DR   KO; K07190; -.
DR   OMA; LKGKYGF; -.
DR   OrthoDB; EOG091G0183; -.
DR   PhylomeDB; Q93100; -.
DR   TreeFam; TF313970; -.
DR   BioCyc; MetaCyc:HS02424-MONOMER; -.
DR   Reactome; R-HSA-70221; Glycogen breakdown (glycogenolysis).
DR   UniPathway; UPA00163; -.
DR   ChiTaRS; PHKB; human.
DR   GeneWiki; PHKB; -.
DR   GenomeRNAi; 5257; -.
DR   PRO; PR:Q93100; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000102893; -.
DR   CleanEx; HS_PHKB; -.
DR   ExpressionAtlas; Q93100; baseline and differential.
DR   Genevisible; Q93100; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005964; C:phosphorylase kinase complex; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0004689; F:phosphorylase kinase activity; IEA:Ensembl.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0005980; P:glycogen catabolic process; TAS:Reactome.
DR   GO; GO:0005977; P:glycogen metabolic process; TAS:ProtInc.
DR   InterPro; IPR008928; 6-hairpin_glycosidase-like.
DR   InterPro; IPR011613; Glyco_hydro_15/PHK.
DR   InterPro; IPR008734; PHK_A/B_su.
DR   PANTHER; PTHR10749; PTHR10749; 1.
DR   Pfam; PF00723; Glyco_hydro_15; 1.
DR   SUPFAM; SSF48208; SSF48208; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Calmodulin-binding;
KW   Carbohydrate metabolism; Cell membrane; Complete proteome;
KW   Disease mutation; Glycogen metabolism; Glycogen storage disease;
KW   Lipoprotein; Membrane; Phosphoprotein; Polymorphism; Prenylation;
KW   Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P12798}.
FT   CHAIN         2   1093       Phosphorylase b kinase regulatory subunit
FT                                beta.
FT                                /FTId=PRO_0000057736.
FT   REGION        7     29       Calmodulin-binding. {ECO:0000255}.
FT   REGION      768    795       Calmodulin-binding. {ECO:0000255}.
FT   REGION      920    951       Calmodulin-binding. {ECO:0000255}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P12798}.
FT   MOD_RES      12     12       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     701    701       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P12798}.
FT   LIPID      1090   1090       S-farnesyl cysteine.
FT                                {ECO:0000250|UniProtKB:P12798}.
FT   VAR_SEQ       1     23       MAGAAGLTAEVSWKVLERRARTK -> MACSPDAVVSPSSA
FT                                FL (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_012445.
FT   VAR_SEQ     780    806       LAVRYGAAFTQKFSSSIAPHITTFLVH -> SVVRRAASLL
FT                                SKVVDSLAPSITNVLVQ (in isoform 3 and
FT                                isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_012446.
FT   VARIANT     118    118       A -> P (in GSD9B; dbSNP:rs121918022).
FT                                {ECO:0000269|PubMed:9402963}.
FT                                /FTId=VAR_015536.
FT   VARIANT     657    657       Q -> K (in dbSNP:rs34667348).
FT                                {ECO:0000269|PubMed:12825073}.
FT                                /FTId=VAR_020857.
FT   VARIANT     770    770       Y -> C (in dbSNP:rs16945474).
FT                                {ECO:0000269|PubMed:12825073,
FT                                ECO:0000269|PubMed:9326319}.
FT                                /FTId=VAR_006187.
FT   VARIANT     820    820       E -> V (in dbSNP:rs9934849).
FT                                /FTId=VAR_034056.
FT   VARIANT     867    867       L -> V (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036486.
FT   VARIANT     877    877       G -> R (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs150902092).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036487.
SQ   SEQUENCE   1093 AA;  124884 MW;  48F05EE306195472 CRC64;
     MAGAAGLTAE VSWKVLERRA RTKRSGSVYE PLKSINLPRP DNETLWDKLD HYYRIVKSTL
     LLYQSPTTGL FPTKTCGGDQ KAKIQDSLYC AAGAWALALA YRRIDDDKGR THELEHSAIK
     CMRGILYCYM RQADKVQQFK QDPRPTTCLH SVFNVHTGDE LLSYEEYGHL QINAVSLYLL
     YLVEMISSGL QIIYNTDEVS FIQNLVFCVE RVYRVPDFGV WERGSKYNNG STELHSSSVG
     LAKAALEAIN GFNLFGNQGC SWSVIFVDLD AHNRNRQTLC SLLPRESRSH NTDAALLPCI
     SYPAFALDDE VLFSQTLDKV VRKLKGKYGF KRFLRDGYRT SLEDPNRCYY KPAEIKLFDG
     IECEFPIFFL YMMIDGVFRG NPKQVQEYQD LLTPVLHHTT EGYPVVPKYY YVPADFVEYE
     KNNPGSQKRF PSNCGRDGKL FLWGQALYII AKLLADELIS PKDIDPVQRY VPLKDQRNVS
     MRFSNQGPLE NDLVVHVALI AESQRLQVFL NTYGIQTQTP QQVEPIQIWP QQELVKAYLQ
     LGINEKLGLS GRPDRPIGCL GTSKIYRILG KTVVCYPIIF DLSDFYMSQD VFLLIDDIKN
     ALQFIKQYWK MHGRPLFLVL IREDNIRGSR FNPILDMLAA LKKGIIGGVK VHVDRLQTLI
     SGAVVEQLDF LRISDTEELP EFKSFEELEP PKHSKVKRQS STPSAPELGQ QPDVNISEWK
     DKPTHEILQK LNDCSCLASQ AILLGILLKR EGPNFITKEG TVSDHIERVY RRAGSQKLWL
     AVRYGAAFTQ KFSSSIAPHI TTFLVHGKQV TLGAFGHEEE VISNPLSPRV IQNIIYYKCN
     THDEREAVIQ QELVIHIGWI ISNNPELFSG MLKIRIGWII HAMEYELQIR GGDKPALDLY
     QLSPSEVKQL LLDILQPQQN GRCWLNRRQI DGSLNRTPTG FYDRVWQILE RTPNGIIVAG
     KHLPQQPTLS DMTMYEMNFS LLVEDTLGNI DQPQYRQIVV ELLMVVSIVL ERNPELEFQD
     KVDLDRLVKE AFNEFQKDQS RLKEIEKQDD MTSFYNTPPL GKRGTCSYLT KAVMNLLLEG
     EVKPNNDDPC LIS
//
